Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recent medical advances have generated a doubling in life expectancy in the industrialized world. It is well documented that the elderly immune system is unable to fight off infections and fails to respond optimally to vaccinations, contributing to morbidity in old age. The reasons behind the decline of the immune system are not clear. Our hypothesis is that long-lived immune cells have developed a strict regime of waste disposal, called autophagy, that becomes less efficient with age. Autophagy removes obsolete organelles and proteins, preventing, cellular damage or death. We aim to identify cellular pathways that control longevity, which is a central goal in stem cell and cancer biology. We aim to develop novel drugs that rejuvenate stem cells and other long-lived cells such as memory cells via autophagy.

Similar stories

T cell Immunotherapy animation launched

A new animation explores work by the Chakraverty Group, Vyas Group, and Professor Borrow from the Jenner Institute.

Irene Roberts delivers Ham-Wasserman Lecture

Presented at the American Society of Hematology Annual Meeting, the award and lectureship recognises individuals from outside the United States who have made significant contributions to Haematology.

Asger Jakobsen receives ASH-BSH Abstract Achievement Award

Dr Jakobsen, a Clinical Research Fellow and DPhil student from the Vyas Group has received the award from the American Society of Hematology and the British Society of Haematology.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.